Albemarle Past Earnings Performance
Past criteria checks 0/6
Albemarle has been growing earnings at an average annual rate of 12.8%, while the Chemicals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 24.8% per year.
Key information
12.8%
Earnings growth rate
11.5%
EPS growth rate
| Chemicals Industry Growth | 20.4% |
| Revenue growth rate | 24.8% |
| Return on equity | -17.4% |
| Net Margin | -30.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Albemarle makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,502 | -1,967 | 647 | 89 |
| 30 Jun 24 | 7,458 | -554 | 655 | 88 |
| 31 Mar 24 | 8,398 | 326 | 654 | 89 |
| 31 Dec 23 | 9,617 | 1,573 | 644 | 86 |
| 30 Sep 23 | 9,882 | 3,324 | 570 | 83 |
| 30 Jun 23 | 9,663 | 3,918 | 532 | 80 |
| 31 Mar 23 | 8,773 | 3,675 | 483 | 76 |
| 31 Dec 22 | 7,320 | 2,690 | 439 | 72 |
| 30 Sep 22 | 5,593 | 1,554 | 393 | 64 |
| 30 Jun 22 | 4,332 | 264 | 365 | 59 |
| 31 Mar 22 | 3,626 | 281 | 363 | 55 |
| 31 Dec 21 | 3,328 | 124 | 333 | 54 |
| 30 Sep 21 | 3,313 | 212 | 450 | 57 |
| 30 Jun 21 | 3,229 | 703 | 439 | 58 |
| 31 Mar 21 | 3,219 | 364 | 418 | 58 |
| 31 Dec 20 | 3,129 | 376 | 427 | 59 |
| 30 Sep 20 | 3,242 | 382 | 411 | 58 |
| 30 Jun 20 | 3,375 | 438 | 430 | 60 |
| 31 Mar 20 | 3,496 | 507 | 453 | 59 |
| 31 Dec 19 | 3,589 | 533 | 470 | 58 |
| 30 Sep 19 | 3,519 | 572 | 440 | 60 |
| 30 Jun 19 | 3,417 | 547 | 432 | 61 |
| 31 Mar 19 | 3,385 | 695 | 417 | 64 |
| 31 Dec 18 | 3,375 | 694 | 415 | 70 |
| 30 Sep 18 | 3,311 | 346 | 410 | 75 |
| 30 Jun 18 | 3,288 | 335 | 416 | 80 |
| 31 Mar 18 | 3,172 | 135 | 421 | 81 |
| 31 Dec 17 | 3,072 | 55 | 420 | 79 |
| 30 Sep 17 | 2,911 | 315 | 431 | 77 |
| 30 Jun 17 | 2,810 | 302 | 416 | 75 |
| 31 Mar 17 | 2,742 | 282 | 396 | 78 |
| 31 Dec 16 | 2,677 | 442 | 355 | 79 |
| 30 Sep 16 | 2,703 | 560 | 303 | 82 |
| 30 Jun 16 | 2,742 | 510 | 297 | 84 |
| 31 Mar 16 | 2,791 | 468 | 299 | 86 |
| 31 Dec 15 | 2,826 | 302 | 300 | 89 |
| 30 Sep 15 | 2,702 | 124 | 397 | 89 |
| 30 Jun 15 | 2,652 | 149 | 382 | 89 |
| 31 Mar 15 | 2,538 | 190 | 361 | 89 |
| 31 Dec 14 | 2,446 | 203 | 355 | 88 |
| 30 Sep 14 | 2,487 | 377 | 183 | 88 |
| 30 Jun 14 | 2,435 | 388 | 178 | 85 |
| 31 Mar 14 | 2,408 | 385 | 173 | 85 |
| 31 Dec 13 | 2,394 | 409 | 158 | 82 |
Quality Earnings: A1LB34 is currently unprofitable.
Growing Profit Margin: A1LB34 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A1LB34 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.8% per year.
Accelerating Growth: Unable to compare A1LB34's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A1LB34 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-6.6%).
Return on Equity
High ROE: A1LB34 has a negative Return on Equity (-17.39%), as it is currently unprofitable.